NCT03385226 2024-12-09
PORT
University College, London
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT03063632 2023-10-25
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02243579 2019-09-20
Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
National Cancer Institute (NCI)
Phase 2 Completed